<DOC>
	<DOCNO>NCT00000721</DOCNO>
	<brief_summary>To determine maximal safe daily dose BG8962 ( rCD4 ) administer continuous subcutaneous infusion ( CSCI ) 24 hour ; determine pharmacokinetics BG8962 administer intramuscular subcutaneous route ; look dose related antiviral activity determine quantitation infectious HIV peripheral blood leukocyte ( PBLs ) plasma , monitor blood level viral p24 antigen ( present ) , CD4+ T-cells , Beta-2- microglobulin . Recombinant soluble CD4 protein ( rCD4 ) drug produce genetic engineering technique . In laboratory study , rCD4 bind HIV reduce ability enter cell , thus inhibit reproduction . Before rCD4 test therapeutic effectiveness HIV-infected patient , necessary determine maximum dose tolerate human . AMENDED : To date , Biogen 's original sequence recombinant soluble CD4 Biogen 's natural sequence recombinant soluble CD4 refer recombinant soluble CD4 ( rsCD4 ) . In order distinguish two product , change nomenclature make . In protocol , whenever original sequence CD4 molecule refer , call recombinant soluble T4 ( rsT4 ) . Whenever natural sequence molecule ( currently study protocol ) refer , call BG8962 rCD4 . Whenever drug discuss generically , refer rsCD4 .</brief_summary>
	<brief_title>An Escalating Dose Tolerance Trial BG8962 ( rCD4 ) Patients Who Are HIV Antibody Positive</brief_title>
	<detailed_description>Recombinant soluble CD4 protein ( rCD4 ) drug produce genetic engineering technique . In laboratory study , rCD4 bind HIV reduce ability enter cell , thus inhibit reproduction . Before rCD4 test therapeutic effectiveness HIV-infected patient , necessary determine maximum dose tolerate human . AMENDED : To date , Biogen 's original sequence recombinant soluble CD4 Biogen 's natural sequence recombinant soluble CD4 refer recombinant soluble CD4 ( rsCD4 ) . In order distinguish two product , change nomenclature make . In protocol , whenever original sequence CD4 molecule refer , call recombinant soluble T4 ( rsT4 ) . Whenever natural sequence molecule ( currently study protocol ) refer , call BG8962 rCD4 . Whenever drug discuss generically , refer rsCD4 . The initial dose level high dose previously establish patient trial safe administer intramuscularly ( IM ) . Dose escalation semilogarithmic step . A shift IM injection continuous subcutaneous infusion ( CSCI ) necessitate volume drug administer part escalation dose . Three group eight patient treat follow . The first group 8 patient receive BG8962 daily consist two cohort four patient . One cohort receive BG8962 IM injection . The second cohort receives BG8962 continuous 24 hour infusion . All patient group treat 12 week . The second dosing group 8 patient receive daily BG8962 CSCI 12 week . The third group 8 patient receive BG8962 CSCI 6 week . Every two week study follow test evaluation do : Blood chemistry , hematology , urinalysis microscopic exam , T-cells T-cell subset .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Nystatin clotrimazole suppression oral thrush . Aerosolized pentamidine Pneumocystis prophylaxis Group A patient . Trimethoprim / sulfamethoxazole Pneumocystis prophylaxis patient hematologically stable trimethoprim / sulfamethoxazole . Patients must : Group A : AIDS symptom define disease status . Group B : AIDS relate complex ( ARC ) symptom define disease status . Exclusion Criteria Coexisting Condition : Patients follow disease condition exclude : Malignancies Kaposi 's sarcoma . AIDS dementia . Opportunistic infection require ongoing therapy except oral thrush suppression nystatin clotrimazole Pneumocystis prophylaxis Group A patient . Significant organ system dysfunction include : Granulocytopenia granulocyte count &lt; 1000 cells/mm3 . Thrombocytopenia &lt; 75000 platelets/mm3 . Anemia hemoglobin &lt; 9.5 g/dl . Renal dysfunction creatinine &gt; 2 mg/dl . Hepatic dysfunction enzyme bilirubin &gt; 3 x upper limit normal . Patients follow exclude : Preexisting antibody rCD4 . Malignancies Kaposi 's sarcoma . AIDSdementia complex . Opportunistic infection require ongoing therapy . Significant organ system dysfunction . Inability sign voluntarily consent form . Prior Medication : Excluded : Recombinant soluble CD4 protein ( rCD4 ) . Excluded within 30 day study entry : Immunomodulatory therapy agent antiHIV activity . Chemotherapy . Prior Treatment : Excluded within 30 day study entry : Radiotherapy . Active illicit drug use alcohol abuse time entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Injections , Subcutaneous</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>